RESUMO
We examined alpha-, beta-, and gamma-T cell receptor (TCR) gene activation within acute lymphoblastic leukemias (ALLs) that represent early stages of B and T cell development. We wished to determine if TCR rearrangement and expression was lineage restricted, showed any developmental hierarchy, or could identify new subsets of T cells. Rearrangement of gamma and beta TCR genes occurred early in development but in no set order, and most T-ALLs (22/26) were of sufficient maturity to have rearranged both genes. T-ALLs preferentially rearranged C gamma 2 versus the C gamma 1 complex; no preference within the beta locus was apparent. Once rearranged, the beta TCR continued to be expressed (11/13), whereas the gamma TCR was rarely expressed (3/14). The alpha TCR was expressed only in more mature T-ALLs (8/14) that usually displayed T3. The 3A-1 T cell associated antigen appeared earliest in development followed by T11 and T3. Within pre-B cell ALL a higher incidence of lineage spillover was noted for gamma TCR rearrangements (8/17) than for beta rearrangements (3/17). This also contrasts with the only occasional rearrangement of immunoglobulin (Ig) heavy chains (3/25) in T-ALL. However, in pre-B ALL the pattern of gamma TCR usage was distinct from that of T cells, with the C gamma 1 complex utilized more frequently. Almost all ALLs could be classified as pre-B or T cell in type by combining Ig and TCR genes with monoclonal antibodies recognizing surface antigens, although examples of lineage duality were noted. Unique subpopulations of cells were discovered including two genetically uncommitted ALLs that failed to rearrange either Ig or TCR loci. Moreover, two T lymphoblasts were identified that possessed the T3 molecule but failed to express alpha plus beta TCR genes. These T-ALLs may represent a fortuitous transformation of T cell subsets with alternative T3-Ti complexes.
Assuntos
Linfócitos B/fisiologia , Leucemia Linfoide/genética , Receptores de Antígenos de Linfócitos T/genética , Linfócitos T/fisiologia , Diferenciação Celular , Regulação da Expressão Gênica , Genes , Humanos , Imunoglobulinas/genética , Leucemia Linfoide/patologia , RNA Mensageiro/genética , Recombinação Genética , Ativação TranscricionalRESUMO
Germline p53 mutations have been identified in the Li-Fraumeni syndrome but the role of such mutations in familial leukemia is not established. The p53 gene was examined by single-strand conformation polymorphism analysis of exons 4-8 in 10 families with multiple members affected with leukemia. The diagnoses included acute and chronic leukemias and Hodgkin's disease. Identified in two families were p53 mutations that were nonhereditary. These included a 2-bp deletion in exon 6 found in the lymphoblast DNA of one child whose sibling, cousin, and several adult relatives had acute leukemia. The other nonhereditary p53 mutation was a transition at codon 248 (CGG to CAG, arginine to glutamine) found in the lymphoblasts of a patient with a preleukemic syndrome and acute lymphoblastic leukemia (ALL) whose brother is a long-term survivor of ALL. Thus, p53 mutations were found to occur in two families but both were nonhereditary. Moreover, in the remaining eight families no p53 mutation was identified in the regions of p53 where most mutations have been found in other cancers. Although p53 mutations sometimes may be present, they do not appear to be a primary event responsible for hereditary susceptibility to familial leukemia. This study suggests involvement of other genes or mechanisms.
Assuntos
Genes p53 , Leucemia/genética , DNA de Neoplasias/genética , Humanos , Mutação , Linhagem , Reação em Cadeia da Polimerase , Mapeamento por RestriçãoRESUMO
The p53 gene was examined in primary lymphoblasts of 25 pediatric patients with acute lymphoblastic leukemia by the RNase protection assay and by single strand conformation polymorphism analysis in 23 of 25 cases. p53 mutations were found to occur, but at a low frequency (4 of 25). While all four mutations were identified by single strand conformation polymorphism, the comparative sensitivity of RNase protection was 50% (2 of 4). Heterozygosity was retained at mutated codons in 3 of 4 cases. One pedigree was consistent with the Li-Fraumeni syndrome, and bone marrow from both diagnosis and remission indicated a germline G to T transversion at codon 272 (valine to leucine). Although members of another family were affected with leukemia, a 2-bp deletion in exon 6 was nonhereditary. The other two nonhereditary p53 mutations included a T to G transversion at codon 270 (phenylalanine to cysteine) and a G to C transversion at codon 248 (arginine to proline). These data support the role of both hereditary and acquired p53 mutations in the pathogenesis and/or progression of some cases of childhood acute lymphoblastic leukemia.
Assuntos
Genes p53 , Mutação , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Adolescente , Adulto , Sequência de Bases , Linfoma de Burkitt/genética , Criança , Pré-Escolar , Deleção Cromossômica , Humanos , Lactente , Recém-Nascido , Síndrome de Li-Fraumeni/genética , Dados de Sequência Molecular , Polimorfismo GenéticoRESUMO
Translocations at chromosomal band 11q23 characterize most de novo acute lymphoblastic leukemias (ALL) of infants, acute myeloid leukemias (AML) of infants and young children, and secondary AMLs following epipodophyllotoxin exposure. The chromosomal breakpoints at 11q23 have been cloned from isolated cases of de novo ALL and AML. Using an 859-base pair BamHI fragment of human ALL-1 complementary DNA that recognizes the genomic breakpoint region for de novo ALL and AML, we investigated two cases of secondary AML that followed etoposide-treated primary B-lineage ALL. In the first case, the translocation occurred between chromosomes 9 and 11 and the breakpoint at 11q23 localized to the same 9-kilobase region of the ALL-1 gene that is disrupted in most of the de novo leukemias. In the second case the translocation was between chromosomes 11 and 19. The breakpoint occurred outside of the ALL-1 breakpoint cluster region.
Assuntos
Leucemia Monocítica Aguda/genética , Podofilotoxina/efeitos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Pré-Escolar , Cromossomos Humanos Par 11/efeitos dos fármacos , Cromossomos Humanos Par 11/fisiologia , DNA de Neoplasias/genética , DNA de Neoplasias/metabolismo , DNA-Citosina Metilases/metabolismo , Etoposídeo/efeitos adversos , Etoposídeo/uso terapêutico , Humanos , Leucemia Monocítica Aguda/induzido quimicamente , Masculino , Segunda Neoplasia Primária/induzido quimicamente , Segunda Neoplasia Primária/genética , Podofilotoxina/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Translocação Genética/efeitos dos fármacosRESUMO
We demonstrated a germline p53 replication error in two generations of a Li-Fraumeni family affected with liposarcoma, adrenocortical carcinoma, and osteosarcoma. The trinucleotide repeat mutation changed 5'-AGT GTG GTG GTG-3' at codons 215-218 to 5'-AGT TGG TTG GTG GTG-3'. The predicted protein would be elongated by one amino acid (val216-->trp leu) without a change in charge. Detection of p53 in the adrenal tumor by immunostaining suggested that the mutant protein was expressed. Persistence of the mutation in the germline may suggest a defect in DNA repair in the family member first affected. This is the first report where germline transmission of replication-damaged p53 trinucleotide repeats is associated with the Li-Fraumeni syndrome.
Assuntos
Genes p53/genética , Síndrome de Li-Fraumeni/genética , Mutação Puntual/genética , Neoplasias do Córtex Suprarrenal/genética , Neoplasias do Córtex Suprarrenal/metabolismo , Adulto , Sequência de Bases , Feminino , Humanos , Lactente , Síndrome de Li-Fraumeni/metabolismo , Lipossarcoma/genética , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Osteossarcoma/genética , Linhagem , Cordão Espermático , Proteína Supressora de Tumor p53/metabolismoRESUMO
Human leukemias with 11q23 translocations occur sporadically and after cancer treatment with DNA topoisomerase II-targeted drugs. To investigate this process, we examined DNA topoisomerase II cleavage in vitro in subclones of the normal 11q23 genomic homologue and a t(9;11) translocation breakpoint junction. Cleavage was assayed with limiting dilutions of enzyme in the presence or absence of epipodophyllotoxin and ATP. The strongest sites of cleavage coincided with the t(9;11) breakpoint site and two other translocation breakpoint sites within the normal homologue. These results support the involvement of DNA topoisomerase II in the translocation process at chromosome band 11q23.
Assuntos
Cromossomos Humanos Par 11 , Cromossomos Humanos Par 9 , DNA Topoisomerases Tipo II/fisiologia , Proto-Oncogenes , Fatores de Transcrição , Translocação Genética , Sequência de Bases , Proteínas de Ligação a DNA/genética , Histona-Lisina N-Metiltransferase , Humanos , Íntrons , Dados de Sequência Molecular , Proteína de Leucina Linfoide-MieloideRESUMO
We have examined a t(9;11)(p22;q23) chromosome translocation in an acute myeloid leukemia of an infant. The breakpoints on the two chromosomes occurred within introns of the involved genes: AF-9 on chromosome 9, and ALL-1 on chromosome 11. Sequence analysis identified heptamers flanking the breakpoints on both chromosomes 9 and 11, suggesting that the V-D-J recombinase was involved in the translocation. The presence of an N-region between the two chromosomes supports the hypothesis that a mistake in V-D-J joining was involved in the genesis of the translocation and indicates that terminal deoxynucleotidyl transferase was expressed in the cells from which this acute myeloid leukemia originated. In addition, potential topoisomerase II DNA-binding sites were found near the breakpoints of both chromosomes, suggesting the involvement of altered topoisomerase II activity in this translocation. Altered topoisomerase II activity in the presence of an active V-D-J recombinase may be a pathogenetic mechanism of acute myeloid leukemia with rearrangements at 11q23.
Assuntos
Cromossomos Humanos Par 9 , DNA Topoisomerases Tipo II/metabolismo , DNA de Neoplasias/metabolismo , Leucemia Mieloide Aguda/genética , Translocação Genética , Sequência de Aminoácidos , Sequência de Bases , Sítios de Ligação , Southern Blotting , Cromossomos Humanos Par 11 , DNA Nucleotidiltransferases/metabolismo , Humanos , Íntrons , Leucemia Mieloide Aguda/metabolismo , Dados de Sequência Molecular , Mapeamento por Restrição , Homologia de Sequência do Ácido Nucleico , VDJ RecombinasesRESUMO
The p53 gene was examined in primary or metastatic tumors from six patients with rhabdomyosarcoma (RMS) and in five RMS cell lines by screening methods including single-strand conformation polymorphism analysis, the RNase protection assay, sequencing of complementary DNA subclones, and Southern blotting. Six original tumors were of embryonal histology, four alveolar, and one mixed. p53 mutations were identified in four of the six tumors or cell lines derived from tumors with embryonal histology and in one of the four with alveolar histology. Consistent with p53 allele loss, each mutation was found in the homo- or hemizygous state. One tumor showed a G to C transversion at p53 codon 213 (arginine to proline), and another showed deletion of the entire gene. The p53 mutations in cell lines included a codon 248 C to T transition (arginine to tryptophan) in RD and a codon 280 A to T transversion (arginine to serine) in RH30. The cell line CTR contained a 4-base pair deletion at codons 219/220 in exon 6 with resultant frame shift and premature termination in exon 7. These data support the role of diverse types of p53 mutations in the pathogenesis and/or progression of a significant proportion of cases of childhood RMS.
Assuntos
DNA de Neoplasias/genética , Frequência do Gene/genética , Genes p53/genética , Mutação/genética , Rabdomiossarcoma/genética , Adolescente , Adulto , Sequência de Bases , Criança , Pré-Escolar , Códon , Análise Mutacional de DNA , Éxons , Humanos , Lactente , Dados de Sequência Molecular , Células Tumorais CultivadasRESUMO
Super resolution (SR) for real-life video sequences is a challenging problem due to complex nature of the motion fields. In this paper, a novel blind SR method is proposed to improve the spatial resolution of video sequences, while the overall point spread function of the imaging system, motion fields, and noise statistics are unknown. To estimate the blur(s), first, a nonuniform interpolation SR method is utilized to upsample the frames, and then, the blur(s) is(are) estimated through a multi-scale process. The blur estimation process is initially performed on a few emphasized edges and gradually on more edges as the iterations continue. Also for faster convergence, the blur is estimated in the filter domain rather than the pixel domain. The high-resolution frames are estimated using a cost function that has the fidelity and regularization terms of type Huber-Markov random field to preserve edges and fine details. The fidelity term is adaptively weighted at each iteration using a masking operation to suppress artifacts due to inaccurate motions. Very promising results are obtained for real-life videos containing detailed structures, complex motions, fast-moving objects, deformable regions, or severe brightness changes. The proposed method outperforms the state of the art in all performed experiments through both subjective and objective evaluations. The results are available online at http://lyle.smu.edu/~rajand/Video_SR/.
RESUMO
We used single-strand conformation polymorphism (SSCP) analysis of p53 exons 4-8 to screen for possible mutations in 25 pediatric de novo leukemias with translocations of the MLL gene at chromosome band 11q23. Of the 25 patients, 21 were infants. Fifteen cases were acute myeloid leukemia (AML), eight were acute lymphoblastic leukemia (ALL), and two cases were biphenotypic. Nineteen cases were studied at diagnosis and six at time of relapse. p53 mutations were absent in all 19 cases studied at the time of diagnosis. The only mutation was a TGC-->TTC transversion (cys-->phe) at codon 141 in exon 5 in a case of infant ALL at relapse that occurred by subclone evolution after MLL gene translocation. We previously showed that p53 mutations are also absent in pediatric treatment-related leukemias with MLL gene translocations. The absence of p53 mutations at initial transformation may suggest that the anti-apoptotic effect of mutant p53 is not important in leukemias with MLL gene translocations. Alternatively, exogenous DNA damage may be the common feature in treatment-related and de novo cases. Since MLL gene translocations may occur through DNA repair and wild-type p53 is central to DNA repair, the absence of p53 mutations raises the possibility that wild-type p53, not mutant p53, may be important in the genesis of leukemias with these translocations.
Assuntos
Cromossomos Humanos Par 11 , Proteínas de Ligação a DNA/genética , Genes p53 , Leucemia Mieloide Aguda/genética , Modelos Genéticos , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Proto-Oncogenes , Fatores de Transcrição , Translocação Genética , Criança , Pré-Escolar , Bandeamento Cromossômico , Mapeamento Cromossômico , Éxons , Feminino , Histona-Lisina N-Metiltransferase , Humanos , Lactente , Recém-Nascido , Cariotipagem , Masculino , Proteína de Leucina Linfoide-Mieloide , Polimorfismo Conformacional de Fita Simples , Recidiva , Dedos de ZincoRESUMO
A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.
Assuntos
Genes p53 , Mutação , Segunda Neoplasia Primária/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Splicing de RNA , Adulto , Idoso , Sequência de Bases , Criança , Humanos , Síndrome de Li-Fraumeni/genética , Pessoa de Meia-Idade , Dados de Sequência Molecular , Segunda Neoplasia Primária/química , RNA Mensageiro/análise , RNA Neoplásico/análise , Proteína Supressora de Tumor p53/análiseRESUMO
A polymorphism at codon 36 in exon 4 of the p53 gene was identified by single strand conformation polymorphism (SSCP) analysis and direct sequencing of genomic DNA PCR products. The polymorphic allele, present in the heterozygous state in genomic DNAs of four of 100 individuals (4%), changes the codon 36 CCG to CCA, eliminates a FinI restriction site and creates a BccI site. Including this polymorphism there are four known polymorphisms in the p53 coding sequence.
Assuntos
Códon , Genes p53 , Polimorfismo Genético , Sequência de Bases , Humanos , Dados de Sequência Molecular , MutaçãoRESUMO
CD19+ B lineage acute lymphoblastic leukemias (ALLs) with unrearranged Ig and TCR genes are designated germline B lineage ALLs. We used CDR3 PCR to determine whether pediatric germline B lineage ALLs contain minor subclones with rearranged Ig H V genes. In six of seven cases there were no PCR detectable CDR3 rearrangements. One case with a smear pattern on CDR3 PCR contained multiple unique CDR3 sequences at frequencies of 1-2 per 2,600, suggesting that polyclonal B cells were present at low frequency. To verify that the germline patterns were from leukemic cells and evaluate in vivo subclone differentiation, a germline B lineage ALL with the t(4;11) translocation was propagated in severe combined immunodeficient SCID) mice. The Ig and TCR genes in the leukemic cells recovered from mouse tissues were germline by Southern blot analysis except for single rearrangements that suggested subclone evolution at the Ig H and lambda loci in addition to the germline population. No CDR3 sequences were detected, indicating that the observed Ig H gene rearrangement most likely was a DJ joining. This study suggests that the transformed cell in germline B lineage ALL represents an early pro-B cell with limited tendency to further differentiate.
Assuntos
Linfócitos B/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , Complexo Receptor-CD3 de Antígeno de Linfócitos T/genética , Receptores de Antígenos de Linfócitos T/genética , Adolescente , Animais , Sequência de Bases , Southern Blotting , Transformação Celular Neoplásica , Criança , Pré-Escolar , Cromossomos Humanos Par 11 , Cromossomos Humanos Par 4 , Primers do DNA , Citometria de Fluxo , Biblioteca Gênica , Rearranjo Gênico , Rearranjo Gênico do Linfócito T , Genes de Imunoglobulinas , Humanos , Lactente , Recém-Nascido , Camundongos , Camundongos SCID , Dados de Sequência Molecular , Transplante de Neoplasias , Reação em Cadeia da Polimerase , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Complexo Receptor-CD3 de Antígeno de Linfócitos T/biossíntese , Translocação Genética , Transplante HeterólogoRESUMO
The major established cause of acute myeloid leukemia (AML) in the young is cancer chemotherapy. There are two forms of treatment-related AML (t-AML). Each form has a de novo counterpart. Alkylating agents cause t-AML characterized by antecedent myelodysplasia, a mean latency period of 5-7 years and complete or partial deletion of chromosome 5 or 7. The risk is related to cumulative alkylating agent dose. Germline NF-1 and p53 gene mutations and the GSTT1 null genotype may increase the risk. Epipodophyllotoxins and other DNA topoisomerase II inhibitors cause leukemias with translocations of the MLL gene at chromosome band 11q23 or, less often, t(8;21), t(3;21), inv(16), t(8;16), t(15;17) or t(9;22). The mean latency period is about 2 years. While most cases are of French-American-British (FAB) M4 or FAB M5 morphology, other FAB AML subtypes, myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) occur. Between 2 and 12% of patients who receive epipodophyllotoxin have developed t-AML. There is no relationship with higher cumulative epipodophyllotoxin dose and genetic predisposition has not been identified, but weekly or twice-weekly schedules and preceding l-asparaginase administration may potentiate the risk. The translocation breakpoints in MLL are heterogeneously distributed within a breakpoint cluster region (bcr) and the MLL gene translocations involve one of many partner genes. DNA topoisomerase II cleavage assays demonstrate a correspondence between DNA topoisomerase II cleavage sites and the translocation breakpoints. DNA topoisomerase II catalyzes transient double-stranded DNA cleavage and rejoining. Epipodophyllotoxins form a complex with the DNA and DNA topoisomerase II, decrease DNA rejoining and cause chromosomal breakage. Furthermore, epipodophyllotoxin metabolism generates reactive oxygen species and hydroxyl radicals that could create abasic sites, potent position-specific enhancers of DNA topoisomerase II cleavage. One proposed mechanism for the translocations entails chromosomal breakage by DNA topoisomerase II and recombination of DNA free ends from different chromosomes through DNA repair. With few exceptions, treatment-related leukemias respond less well to either chemotherapy or bone marrow transplantation than their de novo counterparts, necessitating more innovative treatments, a better mechanistic understanding of the pathogenesis, and strategies for prevention.
Assuntos
Antineoplásicos Alquilantes/toxicidade , Leucemia Mieloide/induzido quimicamente , Segunda Neoplasia Primária/induzido quimicamente , Proto-Oncogenes , Inibidores da Topoisomerase II , Fatores de Transcrição , Quebra Cromossômica/genética , Dano ao DNA/efeitos dos fármacos , Proteínas de Ligação a DNA/genética , Genes Neoplásicos/genética , Histona-Lisina N-Metiltransferase , Humanos , Proteína de Leucina Linfoide-Mieloide , Podofilotoxina/uso terapêutico , Podofilotoxina/toxicidade , Translocação Genética/genéticaRESUMO
Immunoglobulin (Ig) and T-cell receptor (TCR) genes were examined in the lymphoblasts of 70 children with immunophenotypically defined B-cell precursor acute lymphoblastic leukemia (ALL). The most frequent genes to rearrange were Ig heavy (H) chain (93%) and TCR delta (79%), followed by TCR gamma (49%), Ig kappa and/or lambda light (L) chain (46%), TCR alpha (46%), and TCR beta (29%). Thus, despite their putative "B-cell precursor" lineage, these leukemias manifest a remarkably high incidence of TCR gene rearrangements. While certain patterns predominate, there is considerable heterogeneity in Ig and TCR genotypes in this disease. No significant associations were found between Ig and TCR genotype and commonly used prognostic factors including age, sex, race, WBC, French-American-British (FAB) subtype, or cytogenetics. However, the lymphoblasts of three of six patients who failed to achieve initial remission had germline patterns of every Ig and TCR gene, a genotype not observed in the leukemic cells from any of the 64 patients who achieved complete remission (p2 = .0007). This study suggests that particular Ig and TCR genotypes may be of clinical relevance in childhood B-cell precursor ALL. The finding of rearranged TCR genes in a large proportion of cases raises fundamental questions about early lineage commitment and lymphocyte differentiation along B-cell and T-cell pathways.
Assuntos
Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Receptores de Antígenos de Linfócitos T/análise , Receptores Imunológicos/análise , Adolescente , Adulto , Criança , Pré-Escolar , Rearranjo Gênico do Linfócito T , Genótipo , Humanos , Lactente , Fenótipo , Leucemia-Linfoma Linfoblástico de Células Precursoras B/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , Estudos RetrospectivosRESUMO
Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assembly of immune receptor genes in B-cells and T-cells. The patterns of Ig and TCR genes in B-cell precursor and T-cell ALL of childhood and ALL of infancy are heterogeneous though generally distinctive. The vast majority of cases of B-cell precursor ALL of childhood rearrange Ig heavy (H) chain genes, and 40-50% rearrange Ig light (L) chain genes. In contrast, in ALL of infancy, Ig genes are frequently germline, indicating generally less mature cells of origin in younger patients. Similarly, the vast majority of cases of T-cell ALL of childhood rearrange TCR delta, gamma, and beta genes and approximately one-half rearrange TCR alpha. TCR gene rearrangements are very common in cases of B-cell precursor ALL, but in patterns different from T-cells. In contrast, T ALL cells only infrequently rearrange Ig genes, and TCR gamma rearrangements are not found in ALL of infancy. The demonstration of lineage non-restricted Ig and TCR gene rearrangements raises questions about lymphocyte development and about the 'precursor' nature of ALL. The identification of generally distinctive patterns of these genes creates a foundation for their utilization as markers of minimal and preclinical disease. The extent to which specific immune receptor gene patterns correlate with clinical outcome in ALL warrants further study.
Assuntos
Rearranjo Gênico do Linfócito B , Rearranjo Gênico do Linfócito T , Genes de Imunoglobulinas , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Receptores de Antígenos de Linfócitos T gama-delta/genética , Criança , Pré-Escolar , Células Clonais , Humanos , Lactente , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologiaRESUMO
Translocations involving a breakpoint cluster region of the MLL gene at chromosome band 11q23 are the most common molecular abnormalities in acute leukemias of infants and acute leukemias related to chemotherapy with DNA topoisomerase II inhibitors. Molecular cloning of MLL genomic breakpoints by PCR has previously been difficult because MLL has many translocation partners and several breakpoints involve unknown partner genes. We review a new approach to MLL genomic breakpoint cloning called panhandle PCR. By adding an oligonucleotide sequence to the unknown 3' partner gene that is complementary to a known 5' MLL sequence, we have been able to generate a genomic template with an intrastrand loop for PCR schematically shaped like a pan with a handle. The intrastrand loop contains the translocation breakpoint and unknown partner DNA, while the handle contains the known 5' sequence from MLL and a complement to that sequence. Primers both derived from MLL are used to amplify the breakpoint by panhandle PCR. Panhandle PCR offers the advantage of having specificity for the strand of interest at both primer annealing sites without requiring specific primers for the many partner genes of MLL. Panhandle PCR is a straightforward method that represents a technical advance in MLL genomic breakpoint cloning.
Assuntos
Proteínas de Ligação a DNA/genética , Reação em Cadeia da Polimerase/métodos , Proto-Oncogenes , Fatores de Transcrição , Translocação Genética , Deleção Cromossômica , Histona-Lisina N-Metiltransferase , Humanos , Proteína de Leucina Linfoide-MieloideRESUMO
In B-precursor acute lymphoblastic leukemia (ALL), the nucleotide sequence of the complementarity determining region III (CDRIII) in the rearranged immunoglobulin heavy chain gene (IgH) has been used as a molecular fingerprint to identify the leukemic cells. In a child with B-precursor ALL without central nervous system (CNS) disease at diagnosis and a subsequent isolated CNS relapse, we examined the stability of the rearranged IgH by comparing the nucleotide sequences of the CDRIII in the leukemic cells from the marrow at diagnosis to the sequences in the leukemic cells from the cerebrospinal fluid at relapse. Whereas two of the three IgH sequences isolated from the leukemic cells at CNS relapse were identical to sequences originally isolated from the marrow lymphoblasts at diagnosis, the third CNS sequence was similar but not identical to the third marrow sequence. The third IgH sequence identified in the CNS differed from the marrow sequence only at the variable gene segment adjoining the CDRIII. Using a detection method based on the polymerase chain reaction, the altered IgH sequence identified in the leukemic cells from the cerebrospinal fluid was noted to be present in the CNS at a higher frequency than the related diagnostic sequence and was not detected in the marrow either at diagnosis or at CNS relapse. These findings indicate that the clonal pattern of leukemia in the CNS may differ from that in the marrow.
Assuntos
Neoplasias do Sistema Nervoso Central/genética , Rearranjo Gênico de Cadeia Pesada de Linfócito B , Leucemia-Linfoma Linfoblástico de Células Precursoras B/genética , Sequência de Bases , Biomarcadores Tumorais/genética , Medula Óssea/metabolismo , Neoplasias do Sistema Nervoso Central/líquido cefalorraquidiano , Neoplasias do Sistema Nervoso Central/imunologia , Criança , Feminino , Humanos , Região Variável de Imunoglobulina/genética , Dados de Sequência Molecular , Leucemia-Linfoma Linfoblástico de Células Precursoras B/líquido cefalorraquidiano , Leucemia-Linfoma Linfoblástico de Células Precursoras B/imunologia , RecidivaRESUMO
In her 8 1/2 years of life, a girl with neurofibromatosis type 1 (NF1) developed four sequential primary malignant neoplasms: Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and acute myeloid leukemia. The last three tumors were characterized by chromosomal abnormalities non-randomly associated with that particular disease. There was no evidence of germline p53 mutation or of mutation of p53 in the last two tumors. We hypothesize that an unusual mutation of the NF1 gene in this child promoted growth in tissues where the normal or mutated NF-1 gene product is usually silent or growth inhibitory.
Assuntos
Leucemia Mieloide Aguda/etiologia , Leucemia-Linfoma de Células T do Adulto/etiologia , Meduloblastoma/etiologia , Neoplasias Primárias Múltiplas/etiologia , Neurofibromatose 1/complicações , Tumor de Wilms/etiologia , Medula Óssea/patologia , Neoplasias Encefálicas/etiologia , Neoplasias Encefálicas/patologia , Criança , Feminino , Genes p53 , Humanos , Leucemia Mieloide Aguda/genética , Leucemia-Linfoma de Células T do Adulto/genética , Meduloblastoma/genética , Neoplasias Primárias Múltiplas/genética , Neurofibromatose 1/genética , Tumor de Wilms/genéticaRESUMO
Based upon in vitro evidence of p53 involvement in lymphoid differentiation, we assessed immunoglobulin (Ig) and T-cell receptor (TCR) genes in five acute lymphoblastic leukemias (ALLs) with, and 24 ALLs without p53 mutations to compare their genotypic stages. Using Southern blot analysis and complementarity determining region III polymerase chain reaction (CDRIII PCR), 18 cases of B-lineage ALL and 11 cases of T-ALL were studied. Of 20 specimens from 18 B-lineage ALLs, two of four with p53 mutation and two of 16 without mutation had an unrearranged Ig and TCR genotype (p = 0.16; Fisher's exact test). Of 11 cases of T-ALL, the one case with p53 mutation had a rearranged TCR and Ig genotype and a case without mutation was unrearranged. The study indicates that p53 mutation is an infrequent feature of ALL found, nonetheless, in every genotypic subset. The p53 mutations in cases that do not further rearrange may support p53 involvement in lymphoid differentiation, but the heterogeneity in differentiation stages in cases both with and without p53 mutations suggests that regulation of early lymphoid maturation is multifactorial.